- Comparison of liver injury after transcatheter arterial chemoembolization and hepatic arterial infusion chemotherapy for intermediate and advanced hepatocellular carcinomaLi, R.; Li, W.; Yuan, G.; Li, Q.; Hu, X.; Zhu, P.; Chen, Y.; Su, K.; Guo, Y.; Zang, M.; Chen, J.Annual Meeting of the European-Society-for-Medical-Oncology (ESMO), SINGAPORE, 2023-12-01 To 2023-12-03.
- Neoadjuvant hepatic arterial infusion chemotherapy with FOLFOX could improve outcomes of resectable BCLC stage A/B hepatocellular carcinoma patients beyond Milan criteria: A multi-center, phase 3, randomized, controlled clinical trialWei, Wei; Li, Shaohua; Zhao, Rongce; Cheng, Yuan; Li, Qiang; Lu, Lianghe; Mei, Jie; Shang, Changzhen; Luo, Rui; Pan, Mingxin; Xiang, Bangde; Jiang, Yuchuan; Lei, Qiucheng; Cao, Mingrong; Li, Ji-Bin; Zheng, Lie; Chen, Huanwei; Zhong, Jian-Hong; Zhong, Chong; Guo, RongpingAnnual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Chicago, IL, 2023-06-02 To 2023-06-06.被引 2
- Tyrosine kinase inhibitors and/or immune checkpoint inhibitors is required for improving efficacy of transarterial chemoembolization for hepatocellular carcinoma: A large-scale multicenter real-world study of 582 patientsYuan, G.; Li, R.; Zang, M.; Li, Q.; Hu, X.; Fan, W.; Huang, W.; Ruan, J.; Pang, H.; Chen, J.Annual Meeting of the European-Society-for-Medical-Oncology (ESMO), ELECTR NETWORK, 2022-09-09 To 2022-09-13.
会议论文
TACE combined with apatinib in patients with intermediate and advanced hepatocellular carcionma: A prospective, multi-center, randomized clinical trial
10阅读
